Drugs / 64Cu-ATSM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03951337 | Apr 2019 → Jul 2024 | rectal cancer | Institut Cancerologie de l'Ouest | Unknown | No outcome recorded |
| Phase 2 | NCT00794339 | Jul 2009 → Dec 2011 | cervical cancer | American College of Radiology | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-ATSM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00794339 ↗ |
| Known as | 64Cu-copper(II) diacetylbis(N4-methylthiosemicarbazone) | “This phase II trial is assessing how 64Cu-ATSM (64Cu-copper(II) diacetylbis(N4-methylthiosemicarbazone)) PET/CT scan could predict neo adjuvant treatment response in rectum...” NCT03951337 ↗ |
| Route | Intravenous | “Patients receive copper Cu 64-ATSM IV” NCT00794339 ↗ |